News >

FDA Approves Single-Agent Pembrolizumab or Plus Chemo for Frontline HNSCC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jun 11, 2019

The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma as monotherapy whose tumors express PD-L1 (composite positive score [CPS] ≥1) or in combination with platinum and fluorouracil (FU) for this patient population, irrespective of PD-L1 expression.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x